WHERE IT TREATS Systemic optimization (cellular energy, nervous system, and red blood cell pathways)
Data from the SUSTAIN and SCALE trials demonstrated that semaglutide therapy is associated with reductions in LDL cholesterol, total cholesterol, and triglycerides, alongside modest increases in HDL.[3,8] For patients already managing cardiovascular risk, this creates a meaningful opportunity: GLP-1-related lipid improvement may reduce or eliminate the need for statin therapy, but that conversation should be guided by lab data not assumptions
Yes circadian-aligned eating improves insulin sensitivity, SCFA oscillation, fat oxidation, and GLP-1 responsiveness
Even if there is no longer a shortage of the medications, he said, "I look at it as a difference between shortage and access
7b, c )
Because semaglutide is a relatively new medication, people want to learn about all possible side effects